We and others identified that intrinsic and unprimed RIG-I in tumor and innate immune cells mainly exists as an antitumor molecule, as the expression of RIG-I reduces the proliferation and stemness maintenance of leukemia progenitor cells (26) and improves the antitumor effects of IFN-α therapy in hepatocellular carcinoma patients (27). Here, RIGI is linked to leukemia.